GSK’s Priorix Vaccine Gets FDA Approval for Measles, Mumps and Rubella

GSK has received FDA’s approval for its Priorix vaccine for immunization against measles, mumps and rubella (MMR) in individuals age 12 months and older.

The vaccine has been licensed in more than 100 countries and more than 800 million doses have been distributed to date, the company said.

Measles was declared eliminated in the United States in 2000 but cases have been increasing in recent years and child vaccination rates have declined during the pandemic.

The Centers for Disease Control and Prevention’s vaccine advisory committee will consider the GSK vaccine later this month for formal inclusion in the CDC’s vaccine schedule.